136 related articles for article (PubMed ID: 18536677)
1. Fallout from flip-flops.
Froese P
Nat Biotechnol; 2008 Jun; 26(6):614-5. PubMed ID: 18536677
[No Abstract] [Full Text] [Related]
2. The regulator disapproves.
Nat Biotechnol; 2008 Jan; 26(1):1. PubMed ID: 18182998
[No Abstract] [Full Text] [Related]
3. The Provenge decision.
DeVita VT
Nat Clin Pract Oncol; 2007 Jul; 4(7):381. PubMed ID: 17554239
[No Abstract] [Full Text] [Related]
4. Concerns about Provenge simmer as CMS ponders coverage.
Goozner M
J Natl Cancer Inst; 2011 Feb; 103(4):288-9. PubMed ID: 21303996
[No Abstract] [Full Text] [Related]
5. Listening to Provenge--what a costly cancer treatment says about future Medicare policy.
Chambers JD; Neumann PJ
N Engl J Med; 2011 May; 364(18):1687-9. PubMed ID: 21470004
[No Abstract] [Full Text] [Related]
6. Consultation corner. Prostate cancer vaccine offers new direction.
Drake C
Johns Hopkins Med Lett Health After 50; 2010 Sep; 22(7):6-7. PubMed ID: 20848753
[No Abstract] [Full Text] [Related]
7. Cellular immunotherapy licensed for advanced prostate cancer.
Traynor K
Am J Health Syst Pharm; 2010 Jun; 67(11):862. PubMed ID: 20484204
[No Abstract] [Full Text] [Related]
8. Bush tails follow-ons.
Fox J
Nat Biotechnol; 2008 Apr; 26(4):366. PubMed ID: 18392007
[No Abstract] [Full Text] [Related]
9. Immune-boosting prostate cancer vaccine endorsed by FDA advisors.
McBride D
ONS Connect; 2007 Jul; 22(7):19. PubMed ID: 17694780
[No Abstract] [Full Text] [Related]
10. A prostate cancer 'vaccine' under development.
Mayo Clin Health Lett; 2009 Dec; 27(12):4. PubMed ID: 20082492
[No Abstract] [Full Text] [Related]
11. Abigail Alliance v. Von Eschenbach: restricting access to potentially lifesaving drugs singe 2007.
Goodman AJ
J Contemp Health Law Policy; 2008; 25(1):107-41. PubMed ID: 19137749
[No Abstract] [Full Text] [Related]
12. Landmark approval for Dendreon's cancer vaccine.
DeFrancesco L
Nat Biotechnol; 2010 Jun; 28(6):531-2. PubMed ID: 20531312
[No Abstract] [Full Text] [Related]
13. Drug safety reform at the FDA--pendulum swing or systematic improvement?
McClellan M
N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
[No Abstract] [Full Text] [Related]
14. PDUFA reauthorization--drug safety's golden moment of opportunity?
Hennessy S; Strom BL
N Engl J Med; 2007 Apr; 356(17):1703-4. PubMed ID: 17435082
[No Abstract] [Full Text] [Related]
15. Good law from tragic facts--Congress, the FDA, and preemption.
Annas GJ
N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383
[No Abstract] [Full Text] [Related]
16. Pharmaceuticals and medical devices: FDA oversight.
Berry MD
Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893
[No Abstract] [Full Text] [Related]
17. Cancer vaccine approval could open floodgates.
Nat Med; 2010 Jun; 16(6):615. PubMed ID: 20526296
[No Abstract] [Full Text] [Related]
18. Dendreon vs CMS: why the Provenge coverage controversy is bigger than just one product.
Baghdadi R
Oncology (Williston Park); 2010 Sep; 24(10):881-3. PubMed ID: 21138168
[No Abstract] [Full Text] [Related]
19. Paying for drug approvals--who's using whom?
Avorn J
N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
[No Abstract] [Full Text] [Related]
20. The FDA: is it protecting the public with one hand tied behind its back?
Shedlin RS
Law Med Health Care; 1992; 20(3):253-7. PubMed ID: 1434771
[No Abstract] [Full Text] [Related]
[Next] [New Search]
